Hologic Inc Stock Price, News & Analysis

Hologic (NASDAQ: HOLX) has achieved a significant regulatory milestone with both FDA 510(k) clearance and CE marking for its new Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. These molecular diagnostic tests are designed to detect common bacterial pathogens causing infectious gastroenteritis.

The tests can identify multiple pathogens including Salmonella, Campylobacter, Shigella, E. coli, Vibrio, Yersinia, and Plesiomonas. Running on Hologic's Panther Fusion System, these customizable mini-panel assays offer faster, more efficient testing compared to traditional methods, supporting antimicrobial stewardship and enabling targeted treatment decisions.

The technology addresses a significant health concern, as the U.S. experiences nearly 200 million cases of infectious gastroenteritis annually, with up to 3 million requiring ambulatory visits.

Hologic (NASDAQ: HOLX), a global women's health leader, revealed concerning survey results as it prepares to mark Breast Cancer Awareness Month. A Harris Poll survey of over 1,100 U.S. women showed that 48% of recommended women skip or delay mammograms, despite breast cancer having a 99% survival rate when detected early.

The survey uncovered significant misconceptions: 24% of women aged 18-39 incorrectly believe a healthy lifestyle eliminates breast cancer risk, 66% are unaware that dense breasts increase cancer risk, and 27% don't know that yearly mammograms should begin at age 40. In response, Hologic is expanding its #BustTheMyth campaign to educate women about breast cancer screening through various media channels and educational materials.

Minicarm.com has been appointed as the exclusive U.S. distributor for Hologic's (NASDAQ: HOLX) Fluoroscan® Insight™ FD Mini C-Arm imaging system. This strategic distribution agreement comes as Hologic transitions away from commercial activities related to the Fluoroscan Insight product line.

The agreement positions Minicarm.com to manage the remaining inventory and provide comprehensive support including sales, marketing, training, and customer service across the United States. The Fluoroscan Insight FD system is specifically designed for orthopedic and extremity procedures, offering high-quality real-time fluoroscopic imaging capabilities.

VolitionRx (NYSE AMERICAN: VNRX) has signed a co-marketing agreement with Hologic Diagenode for its Nu.Q® Discover service, which provides epigenetic profiling solutions for drug development and research. The initial one-year agreement could potentially lead to Hologic becoming an exclusive provider of these services.

The Nu.Q® Discover program has an estimated total addressable market of $200 million annually. The partnership leverages Hologic's extensive experience and large client base, having recorded revenues exceeding $4 billion in 2024. The collaboration aims to expand Volition's presence in the pharmaco-epigenetics market by incorporating nucleosome-based biomarkers into Hologic's portfolio for various disease areas including oncology, cardiovascular, and neurodegenerative conditions.

Hologic (Nasdaq: HOLX) is presenting groundbreaking research on its AI-powered mammography technology at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Scotland. Two significant studies demonstrate the technology's capabilities:

The first study at Massachusetts General Hospital analyzed 600 biopsy-proven cancer cases using Hologic's Genius AI Detection 2.0. Results showed higher AI case scores correlated with more aggressive tumors and node-positive cancers. The second study compared AI performance against 108 radiologists reviewing 75 challenging breast cancer cases, with AI showing similar cancer detection rates but higher sensitivity.

Additionally, Hologic is showcasing its Sentimag Gen 3 device for tumor localization and breast cancer staging at EUSOBI, recently launched in Europe following the Endomag acquisition.

[ "AI technology demonstrated comparable performance to radiologists in cancer detection", "AI system showed potential to identify more aggressive cancers earlier", "New Sentimag Gen 3 device expands company's breast surgery portfolio in Europe", "Technology could help address radiologist workforce shortages in mammogram screening" ]

Hologic (Nasdaq: HOLX), a medical technology company focused on women's health, announced its participation in the 23rd Annual Morgan Stanley Global Healthcare Conference. The company will present a fireside chat on September 9th at 10:45 a.m. Eastern Time in New York.

The presentation will be accessible through a live webcast on the investors section of Hologic's website, with the recording remaining available for 30 days following the event.

Hologic (NASDAQ:HOLX) reported strong fiscal Q3 2025 results, with revenue of $1,023.8 million, up 1.2% year-over-year and exceeding guidance. The company delivered GAAP EPS of $0.86 (up 4.9%) and non-GAAP EPS of $1.08 (up 1.9%), surpassing guidance.

Key divisional performance included Diagnostics revenue of $448.9 million (up 1.8%), Breast Health revenue of $365.2 million (down 5.1%), and Surgical revenue of $178.4 million (up 7.1%). The company generated strong cash flow from operations of $343.2 million and successfully refinanced its credit facility with a new $1.17 billion term loan and $1.25 billion revolver.

For Q4 2025, Hologic expects revenue of $1,030-$1,040 million with non-GAAP EPS of $1.09-$1.12, projecting continued growth momentum.

Hologic (NASDAQ: HOLX), a medical technology company focused on women's health, has scheduled its third quarter fiscal 2025 financial results announcement for Wednesday, July 30, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern Time on the same day. Participants can join via phone using specific dial-in numbers or through a webcast. A replay will be available on Hologic's investor relations website for 30 days following the call.

Hologic (NASDAQ: HOLX) announced new data on their Breast Cancer Index® (BCI®) test to be presented at ASCO 2025. The study, analyzing over 2,800 patients, demonstrates the test's significant impact in guiding extended endocrine therapy decisions for early-stage, hormone receptor-positive breast cancer patients. Key findings show that BCI testing changed treatment recommendations in approximately 40% of cases, while increasing physician confidence and patient comfort in treatment decisions. The BCI test is notably the only genomic test recognized by clinical guidelines for informing extended endocrine therapy decisions. Two presentations at ASCO will showcase the BCI Registry Study results and translational data from the TEXT trial, validating the test's ability to assess recurrence risk in premenopausal women.